Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.32 |
| ▸ | PI4KA | P42356 | 2/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22797022 | 0.87 | ADORA2A (0.33) | ACVRL1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL20756209 | 0.79 | ADA (0.41) | — | |
| SCHEMBL20756060 | 0.79 | ADORA2A (0.34) | ACVRL1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL24633373 | 0.76 | ACVRL1 (0.34) | ACVRL1 | |
| SCHEMBL24633433 | 0.76 | TLR7 (0.33) | ACVRL1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL22349649 | 0.74 | TLR7 (0.32) | ACVRL1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL24117695 | 0.71 | TLR7 (0.36) | — | |
| SCHEMBL19354212 | 0.70 | ADORA2A (0.38) | ACVRL1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL19352648 | 0.70 | PI4KA (0.35) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL22349721 | 0.69 | ACVRL1 (0.32) | ACVRL1ADORA2AADORA1ADORA2BPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472826-B2 | Acyclic antivirals | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472826-B2 | Acyclic antivirals | PNP, DUT, TYMP | ACVRL1 1916/4885ADORA2A 161/4885ADORA1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.